Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(4):314-316; doi:10.1093/jnci/91.4.314
© 1999 by Oxford University Press
This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 4, 314-316, February 17, 1999
© 1999 Oxford University Press


NEWS

Awards, Appointments, Announcements

The University of Michigan Health System, Ann Arbor, recently created an endowed professorship to honor Max S. Wicha, M.D., director of the university's Comprehensive Cancer Center. The honor "recognizes his vision and commitment in leading the center from its infancy to its current status as one of the premier centers in the country," the announcement said.



View larger version (118K):
[in this window]
[in a new window]
 
Dr. Max S. Wicha

 
The professorship will be held by the center director at Michigan. While Wicha serves as center director, the professorship will be called the Distinguished Professorship in Oncology. Under subsequent directors, it will be known as the Max S. Wicha, M.D., Distinguished Professorship in Oncology. The professorship was established through private and corporate gifts.

AFLAC Endows Chair

The American Family Life Assurance Co., Columbus, Ga., will donate $1.5 million over the next 3 years to the University of Southern California Norris Cancer Center, Los Angeles, to establish the AFLAC Chair in Cancer Research.

The university announced that Leslie Bernstein, Ph.D., professor of preventive medicine at USC, will be the first to hold the chair. Bernstein is also senior associate dean for faculty affairs at USC and scientific director of the Los Angeles County Cancer Surveillance Program.

AFLAC's president, Daniel P. Amos, said the company believes that establishing the chair will be an important step in furthering progress in cancer research and treatment.

Wharton Promoted

The University of Texas M. D. Anderson Cancer Center, Houston, announced that J. Taylor Wharton, M.D., has been promoted to special assistant to the president. He also will be medical director of the institution's Cancer Consultant Program, a new effort to address a growing demand for second opinions for patients.



View larger version (131K):
[in this window]
[in a new window]
 
Dr. J. Taylor Wharton

 
As special assistant he will coordinate a variety of patient relations activities, including the facilitation of patient access to the center, scheduling, and support to patients and their families. He is formerly chairman of gynecologic oncology at Anderson.

Mirand to Lead Office

The Roswell Park Cancer Institute, Buffalo, N.Y., announced that Edwin A. Mirand, Ph.D., D.Sc., will direct a new Office of Alumni Relations. He is emeritus vice president for educational affairs and emeritus dean of the Roswell Park Graduate Division of the University of Buffalo.

The new office was created to involve alumni in student recruitment, legislative advocacy, career placement, and to establish a Roswell Park Alumni Association.

Rastogi Named by Maxim

Maxim Pharmaceuticals, San Diego, named Ram B. Rastogi, Ph.D., as vice president for clinical affairs. He will manage the company's clinical development program, including the three phase III cancer clinical trials underway for one of its products.

Rastogi had been vice president for product development at PPD Pharmaco, a contract research organization.

Kennedy Is CEO

Cell Therapeutics, Inc., Seattle, named Edward F. Kennedy as its chief operating officer. He had held a variety of positions in sales, marketing, and business development for several pharmaceutical and biotechnology firms.

Cell Therapeutics develops small-molecule drugs that selectively regulate the metabolism of oxidized lipids and phospholipids for treating cancer, and inflammatory and immune diseases.

LSA Appoints Dillon

The Leukemia Society of America, New York, named Hildy J. Dillon as director of its Information Resource Center, which provides patients, their families, and health-care professionals with information about leukemia, lymphoma, Hodgkin's disease, and myeloma.

Dillon most recently had been a consultant for Health Education Technologies, assisting in the development and management of professional medical education programs.

Woelkers to Moffitt

The H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla., appointed Joseph F. Woelkers as vice president for clinical outreach programs. He will develop affiliations with community hospitals and other healthcare organizations.



View larger version (123K):
[in this window]
[in a new window]
 
Joseph F. Woelkers

 
Woelkers had been president and chief executive officer of Healthcare Operations International, Atlanta.

New M.S. Program

The Whitaker Foundation, Rosslyn, Va., is providing funds to launch the nation's first master of science degree program in healthcare technologies management, according to an announcement from the Medical College of Wisconsin and Marquette University, both in Milwaukee.

The two universities, which will offer the program, said it will broaden the scope of studies and career opportunities for engineers, especially biomedical engineers, and enhance their collaboration with physicians and health care providers.

The foundation sponsors biomedical research and education, funding projects worth more than $40 million in 1997, the announcement said.

Major Merger

Hoechst AG, the parent company of Hoechst Marion Roussel, Kansas City, Mo., and Rhone-Poulenc SA announced they have agreed to merge into a new company called Aventis that will be the world's second-largest pharmaceutical company.

The merger is subject to approval by regulatory authorities in the United States and Europe. The full merger is expected to take 2 to 3 years. After regulatory approvals are received, the merger will be presented to the shareholder meetings of both current companies, probably by mid-1999, the announcement said.

Stamp Sales Climb

The U.S. Postal Service announced last month that it sold about 61 million of the breast cancer research stamps since their issuance last summer and had raised about $4.9 million for research.Go



View larger version (90K):
[in this window]
[in a new window]
 
 
The semipostal stamp sells for 40 cents, and the amount collected over regular first class price goes — after expenses are deducted — for breast cancer research (70% to the National Institutes of Health and 30% to the Department of Defense).

The USPS also said it would print another 80 million stamps to assure availability through July 2000. Originally, 200 million were printed, but the brisk sales rapidly dropped inventories.

(Items in "Awards, Appointments, Announcements," are compiled from notices received by the News section. Not all notices are used; all those used are edited.)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?